GO
Loading...

Valeant Pharmaceuticals International Inc

More

  • BOSTON, Oct 21- Allergan Inc said on Tuesday it saw no evidence to support claims by hostile suitors Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management that its chief executive officer had spearheaded a campaign to spread misinformation. Pershing Square, run by billionaire William Ackman, has been working with Valeant for months to...

  • Allergan says it stands by statements on Valeant Tuesday, 21 Oct 2014 | 10:45 AM ET

    BOSTON, Oct 21- Allergan Inc said on Tuesday that it believes there is no evidence to support Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management's claims that its chief executive officer spearheaded a campaign to spread misinformation about Valeant.

  • BOSTON, Oct 20- Billionaire investor William Ackman, whose fund is the largest shareholder in Allergan Inc., and Valeant Pharmaceuticals said the botox maker's Chief Executive Officer David Pyott tried to discredit Valeant as it was making a hostile takeover bid, court documents showed. Ackman's hedge fund has been working with Valeant for months to craft a...

  • BUSINESS-NEWS-SCHEDULE AT 1830 GMT / 2:30 p.m. ET Monday, 20 Oct 2014 | 2:52 PM ET

    International Business Machines Corp reports a marked slowdown in business in September and abandons its 2015 operating earnings target, as weak client spending and a slumping software sector weighed down quarterly revenue. Valeant Pharmaceuticals International Inc says it may raise its bid for Botox maker Allergan Inc to more than $200 per share; the...

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc, according to two people familiar with the matter. The hedge fund, which earlier supported a deal with Valeant, told Allergan CEO David Pyott...

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals, according to two people familiar with the matter. The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said.

  • Oct 20- Valeant Pharmaceuticals International Inc said on Monday that it may raise its bid for Botox maker Allergan Inc after the Canadian company posted a better-than-expected quarterly profit. Allergan stock was up 1.7 percent at $180.45. Valeant's third-quarter results were keenly anticipated for their potential impact on Valeant's bid for Allergan,...

  • Oct 20- Canada's Valeant Pharmaceuticals International Inc, embroiled in a bitter fight to take over Botox maker Allergan Inc, posted a better-than-expected quarterly profit, driven by demand for its skin, neuro and eye drugs. The company also raised its full-year adjusted earnings forecast to $8.22- $8.32 per share from $7.90- $8.10 per share to reflect its...

  • *AbbVie board recommends shareholders vote against deal. *AbbVie to pay Shire $1.64 bln break fee if deal collapses. LONDON, Oct 16- U.S. drugmaker AbbVie has pulled the plug on its plan to buy Dublin- based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.

  • Cramer: Activists are picking on the wrong chiefs Thursday, 9 Oct 2014 | 6:25 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention

  • Midday movers: Tesla, Apple, Yelp & more Thursday, 9 Oct 2014 | 12:59 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Thursday's midday movers.

  • Botox maker Allergan boosts outlook Thursday, 9 Oct 2014 | 10:00 AM ET

    NEW YORK— Allergan, which has been fending off buyout offers from Valeant Pharmaceuticals, boosted its earnings outlook for the year and current quarter. The company now expects third-quarter earnings of between $1.76 per share and $1.78 per share, up from its previous forecast between $1.44 per share and $1.47 per share. Allergan also provided a long-term...

  • Oct 8- If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings. Reuters reported on Tuesday that Actavis plans to approach Allergan about a potential merger, providing an...

  • NEW YORK, Oct 8- Earlier this week, Canada's Valeant Pharmaceuticals International Inc appeared to have its plan to buy Botox maker Allergan Inc all mapped out. However, Valeant's well-laid plans appeared to run into trouble this week, when rival drugmaker Actavis Plc came back into the picture as a possible white knight for Allergan. Meanwhile, a separate person...

  • Early movers: JCP, COST, CMI, GRUB, KRFT, YUM Wednesday, 8 Oct 2014 | 7:48 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, Oct 7- Actavis Plc plans to make a new approach for Allergan Inc about a potential merger, as the Botox maker warms up to the possibility of a sale, said people familiar with the matter. Actavis, which held informal conversations with Allergan in recent months about a possible combination, would like to take a hard look at buying the company and could reach...

  • Midday movers: Allergan, Deere, GoPro & More Tuesday, 7 Oct 2014 | 1:00 PM ET

    Some of Tuesday's midday movers:

  • Goldman tops M&A league, tax inversion deals soar Thursday, 2 Oct 2014 | 2:57 AM ET

    Goldman Sachs led the way in global deal-making in the first nine months of 2014, advising on 30.7 percent of all mergers and acquisitions.

  • BOSTON/ NEW YORK, Oct 1- Prominent investor shareholder advisory firm ISS called on Allergan Inc to give its shareholders a chance to vote on any large, buyout-blocking acquisitions and said the company's board faced a credibility problem, according to a report seen by Reuters.

  • T. Rowe joins concerns over Allergan governance Friday, 26 Sep 2014 | 4:16 PM ET
    A drop of Allergan Inc. Botox is seen on the tip of a needle before being administered by Dr. Keith A. Marcus to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California, U.S., on Tuesday, April 22, 2014.

    Another large shareholder of Botox-maker Allergan is expressing concern over the company's corporate governance amid its fight to hold off hostile acquirer Valeant.